# Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

Study · id `cardio:ct-nct01720719` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01720719](<https://clinicaltrials.gov/study/NCT01720719>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01720719

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT01720719. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT01720719, source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)
- Start date: 2013-05 (registry gives no type) (ClinicalTrials.gov record NCT01720719, source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT01720719, source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)
- Completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT01720719, source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01720719, source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01720719-2016-02-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
- Condition: Fatty Liver
- Condition: Dyslipidemias
- Condition: Diabetes Mellitus
- Intervention (Drug): atorvastatin
- Intervention (Drug): Vitamin E
- Lead sponsor: Xin Gao
- Lead sponsor class: OTHER
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Fatty liver disease (NAFLD / MASLD) (`cardio:nafld`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 30a414b9dfdfd4399c35176f94ef59aadebf0b964806fce784325aacb1bef4a1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
